All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The Multiple Myeloma Hub is pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Ola Landgren, Memorial Sloan Kettering Cancer Center, New York, US, answers the question: Can lenalidomide maintenance lead to increased rates of minimal residual disease-negativity?
Lenalidomide maintenance appears to increase MRD-negativity rates. According to a single-arm phase II study on 100 patients treated with lenalidomide maintenance therapy, a high proportion of patients show evidence of many years sustained MRD-negativity and about 25-30% of patients who enter the study as MRD-positive merge into the group of MRD-negative patients.
Can lenalidomide maintenance lead to increased rates of MRD-negativity?
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox